Pharmaceutical giant (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and profits has gone as quickly as it came.
Today, Pfizer stands roughly where it did before COVID-19 and shares trade at their lowest levels since the initial pandemic market crash in 2020. Is the stock a long-term buy after recently completing a blockbuster $43 billion acquisition?
Here is what investors need to know.
Source Fool.com